ABSTRACT Purpose: To investigate the active ingredients of walnut ointment (WO) and its mechanism in repairing wounds. Methods: The ingredients of WO were detected by gas chromatography–mass spectrometry. The effect of linoleic acid (LA) was tested by in vitro Alamar Blue (AB) reagent. Image J software, histological and immunohistochemical analysis were used to confirm the healing effect of LA in the porcine skin model. The animals were euthanized after the experiment by injection of pentobarbital sodium. Results: LA, 24% in WO, promotes keratinocytes and fibroblasts proliferation, which were 50.09% and 15.07% respectively higher than control (p < 0.05). The healing rate of the LA group (96.02% ± 2%, 98.58% ± 0.78%) was higher than the saline group (82.11% ± 3.37%, 88.72% ± 1.73%) at week 3 and week 4 (p < 0.05). The epidermal thickness of the LA was 0.16 ± 0.04 mm greater and the expression of the P63 and CK10 proteins was stronger in the LA group than the control (p < 0.05). Conclusions: LA, which is the main components in WO can promote full-thickness burning wounds (FBWs) by stimulating cell proliferation and differentiation.

OBJECTIVE: The Global Campaign Against Epilepsy demonstration project in rural China aimed: to reduce the treatment gap and morbidity of people with epilepsy by using community-level interventions; to train and educate health professionals; to dispel stigma; to identify potential for prevention and to develop models of integration of epilepsy control into the local health systems. We report the overall results of the demonstration project, focusing on the prevalence and the change in the treatment gap of epilepsy after an intervention. METHODS: Door-to-door epidemiological surveys were carried out before, and 6 months after the end of, an intervention project for epilepsy in rural settings in five provinces of China. The intervention consisted of a treatment programme available to patients without prior appropriate treatment and a public health educational programme about epilepsy. The sampled population in the second survey was 51 644 people. FINDINGS: In the second survey, epilepsy was confirmed in 320 people, yielding a lifetime prevalence of 6.2/1000 and a prevalence of active epilepsy of 4.5/1000. The lifetime prevalence and prevalence of active epilepsy in the first survey were 7.0/1000 and 4.6/1000, respectively. The treatment gap of active epilepsy in the second survey was 49.8%, 12.8 percentage points lower than that of the first survey (62.6%). CONCLUSION: The results of this study suggest that the intervention measures used were possibly effective and evidently feasible in rural China, contributing to a decrease in the treatment gap of epilepsy.

OBJETIVO: El proyecto piloto de la Campaña Mundial Contra la Epilepsia en la China rural se propuso los siguientes objetivos: reducir la brecha de tratamiento y la morbilidad de las personas con epilepsia aplicando intervenciones comunitarias; capacitar y educar a los profesionales de la salud; combatir la estigmatización; identificar las posibilidades de prevención, y desarrollar modelos de integración del control de la epilepsia en los sistemas de salud locales. Se informa aquí de los resultados globales del proyecto piloto, haciendo hincapié en la prevalencia y en la variación de la brecha de tratamiento de la epilepsia después de una intervención. MÉTODOS: Se llevaron a cabo encuestas epidemiológicas domiciliarias antes de iniciar y a los 6 meses de finalizar un proyecto de intervención contra la epilepsia en entornos rurales de cinco provincias de China. La intervención consistió en un programa terapéutico ofrecido a los pacientes sin tratamiento previo apropiado y un programa de educación de salud pública sobre la epilepsia. La población muestreada en la segunda encuesta fue de 51 644 personas. RESULTADOS: En la segunda encuesta se confirmó la existencia de epilepsia en 320 personas, lo que indica una prevalencia durante toda la vida de 6,2/1000 y una prevalencia de epilepsia activa de 4,5/1000. La prevalencia durante toda la vida y la prevalencia de epilepsia activa en la primera encuesta fueron de 7,0/1000 y 4,6/1000, respectivamente. La brecha terapéutica en el caso de la epilepsia activa en la segunda encuesta fue del 49,8%, un 12,8% menos que en la primera encuesta (62,6%). CONCLUSIÓN: Los resultados de este estudio parecen indicar que las medidas de intervención aplicadas fueron posiblemente eficaces y sin duda factibles en la China rural, reduciéndose en consecuencia la brecha de tratamiento de la epilepsia.

OBJECTIF: Le projet de démonstration en Chine rurale de la Campagne mondiale contre l'épilepsie avait pour objectifs : de réduire l'écart de prise en charge thérapeutique et de morbidité entre les épileptiques faisant appel à des interventions communautaires ; de former et d'éduquer les professionnels de santé ; de dissiper la stigmatisation ; d'identifier les possibilités de prévention et de développement de modèles d'intégration de la lutte contre l'épilepsie dans les systèmes de santé locaux. Nous rendons compte des résultats globaux de ce projet de démonstration, en nous concentrant sur la prévalence et l'évolution du déficit de traitement de l'épilepsie après une intervention. MÉTHODES: Des enquêtes épidémiologiques «porte à porte» ont été effectuées avant et 6 mois après un projet d'intervention concernant l'épilepsie dans des zones rurales de cinq provinces chinoises. L'intervention con sistait en un programme de traitement proposé aux patients n'ayant bénéficié auparavant d'aucun traitement approprié, et en un programme d'éducation en santé publique concernant l'épilepsie. La population échantillonnée dans la seconde enquête comprenait 51 644 personnes. RÉSULTATS: Dans la seconde enquête, l'épilepsie a été confirmée chez 320 personnes, ce qui donne une prévalence sur la durée de vie de 6,2/1000 et une prévalence de l'épilepsie active de 4,5/1000. Dans la première enquête, la prévalence sur la durée de vie et la prévalence de l'épilepsie active étaient respectivement de 7,0/1000 et de 4,6/1000. Le déficit de traitement de l'épilepsie active dans la seconde enquête était de 49,8 %, soit 12,8 % de moins que dans la première enquête (62,6 %). CONCLUSION: Les résultats de cette étude laissent à penser que les mesures d'intervention utilisées pouvaient être efficaces et étaient à l'évidence applicables en Chine rurale, où elles ont contribué à une diminution du déficit de traitement de l'épilepsie.

Foi desenvolvido um método altamente sensível, seletivo e rápido para a determinação de mercúrio, a partir da reação rápida de mercúrio(II) com 5-(p-aminobenzilideno)-tiorodanina (ABTR) e posterior extração em fase sólida do quelato colorido, utilizando discos C18. Em pH 3,5 e na presença do emulsificante-OP, ABTR reage com mercúrio(II) para formar um quelato vermelho na razão molar 1:2 (mercúrio:ABTR). O quelato foi enriquecido pela extração em fase sólida com discos C18 e o quelato retido, eluído com dimethyl formamida (DMF). Um fator de enriquecimento na ordem de 50 foi obtido. Em DMF, a absortividade molar do quelato é 1,21<FONT FACE=Symbol>´</FONT>10(5) L mol-1 cm-1 a 545 nm, e a lei de Beer é obedecida no intervalo 0,01~3 µg mL-1 na solução medida. O desvio padrão relativo para onze replicatas a 0,01 µg mL-1 é 1,7%. Este método foi aplicado para a determinação de mercúrio em tabaco e aditivos de tabaco. Bom coeficiente de preconcentração foi encontrado, comparando-se o método proposto com outros similares.

A highly sensitive, selective and rapid method for the determination of mercury based on the rapid reaction of mercury(II) with 5-(p-aminobenzylidene)-thiorhodanine (ABTR) and the solid phase extraction of the colored chelate with C18 disks has been developed. At pH 3.5 and in the presence of emulsifier-OP medium, ABTR reacts with mercury(II) to form a red chelate of a 1:2 (mercury to ABTR) molar ratio. This chelate was enriched by solid phase extraction with C18 disks and the retained chelate eluted form the disks with dimethyl formamide (DMF). An enrichment factor of 50 was achieved. In the DMF medium, the molar absorptivity of the chelate is 1.21<FONT FACE=Symbol>´</FONT>10(5) L mol-1 cm-1 at 545 nm, and Beer's law is obeyed in the 0.01~3 µg mL-1 range in the measured solution. The relative standard deviation for eleven sample replicate measurements at the 0.01 µg mL-1 level is 1.7%. This method was applied to the determination of mercury in tobacco and tobacco additives and good preconcentration was found between proposed and comparative methods results.